In the Press COUR Pharmaceuticals Doses First Patient in Phase 1b/2a Clinical Trial Evaluating CNP-106 in Generalized Myasthenia Gravis October 2024 Read More COUR Pharmaceuticals Announces Late-Breaking Poster for Phase 2a Data of CNP-104 in Primary Biliary Cholangitis Accepted for Presentation at The Liver Meeting® 2024 October 2024 Read More COUR Pharmaceuticals Announces Positive Top-line Results from Phase 2a Study of CNP-104 in Primary Biliary Cholangitis September 2024 Read More COUR Pharmaceuticals Announces Leadership Transition for Strategic Growth Objectives August 2024 Read More
COUR Pharmaceuticals Doses First Patient in Phase 1b/2a Clinical Trial Evaluating CNP-106 in Generalized Myasthenia Gravis October 2024 Read More
COUR Pharmaceuticals Announces Late-Breaking Poster for Phase 2a Data of CNP-104 in Primary Biliary Cholangitis Accepted for Presentation at The Liver Meeting® 2024 October 2024 Read More
COUR Pharmaceuticals Announces Positive Top-line Results from Phase 2a Study of CNP-104 in Primary Biliary Cholangitis September 2024 Read More
COUR Pharmaceuticals Announces Leadership Transition for Strategic Growth Objectives August 2024 Read More
